All In Biotech

Drug Trial Radar · NCT07606950

Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS-5635 Injection in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Jul 17, 2026

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Sponsor type
Industry
First posted
May 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and immunogenicity of HRS-5635 injection as compared to the placebo arm in nucleos(t)ide analogue-suppressed HBeAg-negative patients with chronic hepatitis B. The total duration of the study, including screening (up to 4 weeks), the double-blind treatment stage (60 weeks),NAs-only treatment stage(12 weeks) and the off-treatment follow-up (24 weeks), is up to approximately 100 weeks at maximum for each participant.

Conditions

  • Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B

Interventions

  • HRS-5635 InjectionDrug

    HRS-5635 Injection, administered by subcutaneous injection;

  • PlaceboDrug

    Placebo, administered by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with sustained HBV DNA suppression and HBsAg loss within 24 weeks after discontinuation of all HBV therapyTime frame: 24 weeks after discontinuation of all CHB treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.